Benzodiazepine use in Sao Paulo, Brazil

Authors

  • Angela Maria Campanha Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, I Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0003-1845-8311
  • Beatriz Ravagnani Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0002-6077-9461
  • Igor André Milhoranc¸a Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0003-3649-0358
  • Márcio Antonini Bernik Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Programa de Ansiedade https://orcid.org/0000-0001-7922-6747
  • Maria Carmen Viana Universidade Federal do Espirito Santo, Centro de Estudos e Pesquisa em Epidemiologia Psiquiatrica, Programa de Pos-Graduacao em Saude Coletiva, Departamento de Medicina Social https://orcid.org/0000-0002-0464-4845
  • Yuan-Pang Wang Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0001-7076-8312
  • Laura Helena Andrade Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0002-2362-3521

DOI:

https://doi.org/10.6061/clinics/2020/e1610

Keywords:

Psychiatry, Pharmacy, Psychotropic Drugs, Hypnotics and Sedatives, Benzodiazepines

Abstract

OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.

Downloads

Download data is not yet available.

Downloads

Published

2020-07-27

How to Cite

Campanha, A. M., Ravagnani, B., Milhoranc¸a, I. A., Bernik, M. A., Viana, M. C., Wang, Y.-P., & Andrade, L. H. (2020). Benzodiazepine use in Sao Paulo, Brazil. Clinics, 75, e1610. https://doi.org/10.6061/clinics/2020/e1610

Issue

Section

Original Articles